{"id":"W2592092676","doi":"10.1200/jco.2009.27.15_suppl.1133","title":"A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pazopanib; Clinical endpoint; Metastatic breast cancer; Adverse effect; Progressive disease; Internal medicine; Phases of clinical research; Progression-free survival; Capecitabine; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Breast cancer; Stage (stratigraphy); Surgery; Oncology; Cancer; Gastroenterology; Clinical trial; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002130198,0.001818146,0.002320446,0.0004398488,0.0003702489,0.000807674,0.0009229862,0.001461847,0.003546873],"category_scores_gemma":[0.001123094,0.0006295416,0.001545409,0.0004672033,0.0008694631,0.0007146084,0.0003277352,0.003384383,0.0009005895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009034813,"about_ca_system_score_gemma":0.001253168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001021596,"about_ca_topic_score_gemma":0.002397161,"domain_scores_codex":[0.9994557,0.0002862111,0.00002142245,0.00007815664,0.00004886288,0.0001095899],"domain_scores_gemma":[0.9989717,0.0001401644,0.0002051084,0.00007545704,0.00005044286,0.000557108],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.791329,0.06820091,0.009035517,0.0008551806,0.001728195,0.0004101914,0.0003249312,0.002029457,0.02864673,0.0002390442,0.007682586,0.08951826],"study_design_scores_gemma":[0.7468094,0.2365346,0.0127382,0.00002113465,0.0003303105,0.0002657692,0.00002562109,0.0007237219,0.00109852,0.0001327399,0.001294889,0.00002507572],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922432,0.002417834,0.000352457,0.0005273174,0.0001201497,0.001697083,0.001060446,0.00007400396,0.001507361],"genre_scores_gemma":[0.986025,0.00259619,0.001189579,0.001302425,0.0003019887,0.002322829,0.00343143,0.00004042518,0.002790184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003546873,"threshold_uncertainty_score":0.01186544,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05649521255339111,"score_gpt":0.4024791046447245,"score_spread":0.3459838920913334,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}